ScoreWhy is CSPC Innovation Pharmaceutical Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 12.25% and Operating profit at -212.20% over the last 5 years
2
The company has declared Negative results for the last 10 consecutive quarters
- ROCE(HY) Lowest at -9.81%
- INVENTORY TURNOVER RATIO(HY) Lowest at 3.51 times
- NET PROFIT(Q) At CNY -95.43 MM has Fallen at -47.33%
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -29.51%, its profits have fallen by -29.6%
- At the current price, the company has a high dividend yield of 0
4
Underperformed the market in the last 1 year
- Even though the market (China Shanghai Composite) has generated returns of 16.83% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -29.51% returns
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to CSPC Innovation Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to FMCG should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in FMCG)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is CSPC Innovation Pharmaceutical Co., Ltd. for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
CSPC Innovation Pharmaceutical Co., Ltd.
-5.42%
0.34
61.81%
China Shanghai Composite
3.23%
1.20
14.07%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
12.25%
EBIT Growth (5y)
-212.20%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.33
Sales to Capital Employed (avg)
0.59
Tax Ratio
10.25%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
21.58%
ROE (avg)
8.09%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
12.29
EV to EBIT
-50.69
EV to EBITDA
-70.20
EV to Capital Employed
18.23
EV to Sales
13.10
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-35.97%
ROE (Latest)
-23.92%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend45What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY 1,774.45 MM
ROCE(HY)
Highest at 26.76%
RAW MATERIAL COST(Y)
Fallen by -177.11% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -93.73 %
DEBTORS TURNOVER RATIO(HY)
Highest at 5.17 times
NET SALES(Q)
Highest at CNY 2,575.6 MM
OPERATING PROFIT(Q)
Highest at CNY 1,751.48 MM
OPERATING PROFIT MARGIN(Q)
Highest at 68 %
PRE-TAX PROFIT(Q)
Highest at CNY 1,678.74 MM
NET PROFIT(Q)
Highest at CNY 1,350.69 MM
EPS(Q)
Highest at CNY 0.97
-8What is not working for the Company
INTEREST(HY)
At CNY 24.29 MM has Grown at 211.46%
Here's what is working for CSPC Innovation Pharmaceutical Co., Ltd.
Net Sales
At CNY 2,575.6 MM has Grown at 338.33%
over average net sales of the previous four periods of CNY 587.59 MMMOJO Watch
Near term sales trend is extremely positive
Net Sales (CNY MM)
Pre-Tax Profit
At CNY 1,678.74 MM has Grown at 1,332.66%
over average net sales of the previous four periods of CNY -136.19 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CNY MM)
Net Profit
At CNY 1,350.69 MM has Grown at 1,749.06%
over average net sales of the previous four periods of CNY -81.91 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (CNY MM)
Operating Cash Flow
Highest at CNY 1,774.45 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Net Sales
Highest at CNY 2,575.6 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Operating Profit
Highest at CNY 1,751.48 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
Operating Profit Margin
Highest at 68 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at CNY 1,678.74 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Net Profit
Highest at CNY 1,350.69 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
EPS
Highest at CNY 0.97
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CNY)
Debt-Equity Ratio
Lowest at -93.73 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 5.17 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -177.11% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for CSPC Innovation Pharmaceutical Co., Ltd.
Interest
At CNY 24.29 MM has Grown at 211.46%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
